Ellis Sean
Known title: DirectorCIK: 0001904752
Ellis Sean's purchase track record
How the stock did after each of Ellis Sean's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
6
of 6 since January 18, 2022
Stock higher 6 months later
67%
3 months: 50%
Median 6-month return
+80.8%
3 months: +1.5%
Beat the S&P 500
67%
median +72.6% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 3/5/2026 | ENTX | $12K | -0.8% | +139.8% | +13.4% |
| 2/9/2026 | ENTX | $22K | -12.0% | +128.6% | +11.3% |
| 8/21/2023 | ENTX | $24K | +20.7% | +73.6% | +13.1% |
| 11/11/2022 | ENTX | $16K | +82.0% | +88.0% | +3.3% |
| 7/21/2022 | ENTX | $24K | -55.8% | -53.4% | -2.5% |
| 1/18/2022 | ENTX | $28K | +3.9% | -48.9% | -14.0% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| ENTX | ▲ Buy | Grant | 20,034 | $0 | 8/7/2026 | View on chart |
| ENTX | ▲ Buy | Open Market | 10,000 | $12K | 3/5/2026 | View on chart |
| ENTX | ▲ Buy | Open Market | 18,000 | $22K | 2/9/2026 | View on chart |
| ENTX | ▲ Buy | Grant | 25,371 | $0 | 1/1/2026 | View on chart |
| ENTX | ▲ Buy | Grant | 7,100 | $0 | 1/15/2025 | View on chart |
| ENTX | ▲ Buy | Grant | 7,466 | $0 | 10/2/2024 | View on chart |
| ENTX | ▲ Buy | Grant | 18,061 | $0 | 8/27/2024 | View on chart |
| ENTX | ▲ Buy | Open Market | 40,000 | $24K | 8/21/2023 | View on chart |
| ENTX | ▲ Buy | Open Market | 30,000 | $16K | 11/11/2022 | View on chart |
| ENTX | ▲ Buy | Open Market | 14,900 | $24K | 7/21/2022 | View on chart |
| ENTX | ▲ Buy | Open Market | 10,000 | $28K | 1/18/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
Entera Bio gets new coverage from Guggenheim and Cantor
Guggenheim has started coverage of Entera Bio, giving it a buy rating and a target price of $11. Cantor Fitzgerald also began coverage, assigning an overweight rating. These new ratings come as the stock trades near its 52‑week low and shows a moderate RSI of 40, indicating room for movement.
Entera Bio gets new coverage from Guggenheim and Cantor. Guggenheim has started coverage of Entera Bio, giving it a buy rating and a target price of $11. Cantor Fitzgerald also began coverage, assigning an overweight rating. These new ratings come as the stock trades near its 52‑week low and shows a moderate RSI of 40, indicating room for movement.